Naryx Pharma, Inc., a leader in the development of new therapies for patients with chronic sinusitis, has completed enrollment of a 180 subject, randomized, double-blind, placebo-controlled Phase 2b trial of SybryxTM (tobramycin solution for nasal inhalation) for the treatment of chronic sinusitis in patients who have undergone previous sinus surgical procedures. The results of the trial will be announced after unblinding the data in the first quarter of 2008.
Previously, the U.S. Food and Drug Administration had granted Fast Track status to SybryxTM, acknowledging that chronic sinusitis that persists after sinus surgery has a serious and enduring adverse impact on the day-to-day functioning of patients who suffer from the condition. Moreover, there are no currently approved medical therapies for the treatment of chronic sinusitis, and the results of a previous Phase 2a trial demonstrated that SybryxTM relieved the symptoms of chronic sinusitis in post-surgical patients.
Robin Campbell, Ph.D., President and CEO of Naryx Pharma, stated, “We are pleased that we have completed this milestone in the development of SybryxTM and would like to thank all of the investigators who are participating in the trial. Many patients are suffering from chronic sinusitis, and we look forward to continuing to develop a treatment for this serious and sometimes debilitating disease.”
About Naryx Pharma
Naryx™ is a privately-held company dedicated to developing innovative therapies for chronic sinusitis, based on advances in the targeted delivery of medications. Chronic sinusitis is a disease that afflicts up to 35 million people in the U.S. alone. The Company will focus on obtaining marketing approvals for its promising intellectual property portfolio of intranasal drug formulations.